Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Takeda Pharmaceutical Company Limited
< Previous
1
2
3
4
5
Next >
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
July 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
July 21, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
July 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
June 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
June 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
June 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
MRNA
TAK
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
SGEN
TAK
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Completion of Acquisition of Own Shares
April 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
April 12, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
April 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
April 01, 2022
From
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Via
Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
March 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
February 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
February 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
February 03, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
January 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Named Global Top Employer for Fifth Consecutive Year
January 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
December 21, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
December 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
December 08, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.